|
|
|
|
||
KALVKalVista Pharmaceuticals Says KVd900 Phase 2 Clinical Trial For Oral Treatment Of Hereditary Angioedema (HAE) Data Expected In 2H 2020; Oral HAE Prophylactic Candidate KVD824 Phase 2 Clinical Trial Planned To Commence In 2H 2020 |
return to message board, top of board |